Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction

被引:0
|
作者
J D Brioni
M Nakane
G C Hsieh
R B Moreland
T Kolasa
J P Sullivan
机构
[1] Neuroscience Research,
[2] Global Pharmaceutical Research and Development,undefined
[3] Abbott Laboratories,undefined
关键词
guanylate cyclase; YC-1; penile erection; erectile dysfunction; corpus cavernosum; sildenafil; cGMP;
D O I
暂无
中图分类号
学科分类号
摘要
Soluble guanylate cyclase (sGC) is an important enzyme in corpus cavernosum smooth muscle cells as it is one of the regulators of the synthesis of cGMP. The efficacy of sildenafil (Viagra™) in the treatment of male erectile dysfunction indicates the importance of the cGMP system in the erectile response as the increased levels of cGMP induce relaxation of the corpus cavernosum. sGC is physiologically activated by nitric oxide (NO) during sexual stimulation, and its activity can be pharmacologically enhanced by several NO-donors. Agents like YC-1 can also activate sGC after binding to a novel allosteric site in the enzyme, a site different from the NO binding site. YC-1 can relax rabbit cavernosal tissue and it facilitates penile erection in vivo. This review summarizes the enzymology, biochemistry and pharmacology of this novel allosteric site and its relevance for the regulation of penile function. This type of sGC activators represent a new class of compounds with a different pharmacological profile in comparison to the classical NO-donors and they could be beneficial for the treatment of male erectile dysfunction.
引用
收藏
页码:8 / 14
页数:6
相关论文
共 50 条
  • [41] Mechanism of activation of soluble guanylate cyclase by guanidine thiols - A new class of enzyme activators.
    Severina, IS
    Bussygina, OG
    Vinograd, LH
    Grigoryev, NB
    BIOCHEMISTRY AND MOLECULAR BIOLOGY INTERNATIONAL, 1996, 38 (03): : 509 - 518
  • [42] Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence
    Sandner, Peter
    Stasch, Johannes Peter
    RESPIRATORY MEDICINE, 2017, 122 : S1 - S9
  • [43] Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress
    Costell, Melissa H.
    Ancellin, Nicolas
    Bernard, Roberta E.
    Zhao, Shufang
    Upson, John J.
    Morgan, Lisa A.
    Maniscalco, Kristeen
    Olzinski, Alan R.
    Ballard, Victoria L. T.
    Herry, Kenny
    Grondin, Pascal
    Dodic, Nerina
    Mirguet, Olivier
    Bouillot, Anne
    Gellibert, Francoise
    Coatney, Robert W.
    Lepore, John J.
    Jucker, Beat M.
    Jolivette, Larry J.
    Willette, Robert N.
    Schnackenberg, Christine G.
    Behm, David J.
    FRONTIERS IN PHARMACOLOGY, 2012, 3
  • [44] Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension
    Lian, Tian-Yu
    Jiang, Xin
    Jing, Zhi-Cheng
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 1195 - 1207
  • [45] RIOCIGUAT Soluble Guanylate Cyclase Stimulator Treatment of Pulmonary Hypertension
    Mulligan, C.
    DRUGS OF THE FUTURE, 2009, 34 (06) : 468 - 475
  • [46] Both soluble guanylate cyclase and particulate guanylate cyclase regulate myometrial contractility
    Syal, AS
    Vedernikov, YP
    Chwalisz, K
    Saade, GR
    Garfield, RE
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1998, 179 (01) : 111 - 116
  • [47] Vasomax for the treatment of male erectile dysfunction
    Goldstein, I
    Carson, C
    Rosen, R
    Islam, A
    WORLD JOURNAL OF UROLOGY, 2001, 19 (01) : 51 - 56
  • [48] DIAGNOSIS AND TREATMENT OF MALE ERECTILE DYSFUNCTION
    BEUTLER, LE
    STEINBRONN, D
    BAMFORD, CR
    ARIZONA MEDICINE, 1981, 38 (05) : 351 - 356
  • [49] YOHIMBINE IN THE TREATMENT OF MALE ERECTILE DYSFUNCTION
    ASHTON, AK
    AMERICAN JOURNAL OF PSYCHIATRY, 1994, 151 (09): : 1397 - 1397
  • [50] Vasomax for the treatment of male erectile dysfunction
    Irwin Goldstein
    Culley Carson
    Ray Rosen
    Anita Islam
    World Journal of Urology, 2001, 19 : 51 - 56